0.60Open0.60Pre Close0 Volume2 Open Interest2.50Strike Price0.00Turnover174.30%IV21.49%PremiumDec 20, 2024Expiry Date0.08Intrinsic Value100Multiplier19DDays to Expiry0.52Extrinsic Value100Contract SizeAmericanOptions Type-0.4517Delta0.4128Gamma5.69Leverage Ratio-0.0100Theta-0.0007Rho-2.57Eff Leverage0.0022Vega
ADC Therapeutics Stock Discussion
ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting
ADC Therapeutics (NYSE: ADCT) announced two investigator-initiated study abstracts on ZYNLONTA accepted for presentation at the 66th ASH Annual Meeting. The Phase 2 study combining ZYNLONTA with rituximab in relapsed/refractory follicular lymphomashowed a 97.1% overall response rate among 35 patients, with an 80% best complete metabolic respon...
NEWS
ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants
No comment yet